Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
AssigneeTranscend Therapeutics, Inc.
InventorsBlake MANDELL, Martin STOGNIEW, Jennifer Louise SCHMIDT, Markus SEELIG
Life of this patent
Estimating the term…
Abstract
The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.
Claims37
-10. (canceled)
A method of treating and/or preventing a neuropsychiatric illness and/or ameliorating a symptom thereof in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising methylone (3,4-methylenedioxy-N-methylcathinone) or a pharmaceutically acceptable salt thereof, and/or an enantiomer thereof, and/or an isotopologue thereof, and/or an isotopomer thereof, and/or a solvate thereof, and/or a prodrug thereof, and/or a polymorph thereof.
(canceled)
(canceled)
-21. (canceled)
(canceled)
(canceled)
-64. (canceled)
A method of treating and/or preventing a neuropsychiatric illness and/or ameliorating a symptom thereof in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a serotonin-norepinephrine-dopamine reuptake inhibitor and releaser that lacks agonist or antagonist activity at the 5-HT2A and 5-HT2B receptors.
-73. (canceled)
-109. (canceled)
A method of treating a neuropsychiatric illness, and/or ameliorating a symptom thereof in a human subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising methylone (3,4-methylenedioxy-N-methylcathinone) or a pharmaceutically acceptable salt thereof, and/or an enantiomer thereof, and/or an isotopologue thereof, and/or an isotopomer thereof, and/or a solvate thereof, and/or a polymorph thereof, and/or a prodrug thereof in a therapeutically effective amount that results in a plasma Cmax of methylone of 98-994 ng/ml in the subject.
A method of treating a neuropsychiatric illness, and/or ameliorating a symptom thereof in a human subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising methylone (3,4-methylenedioxy-N-methylcathinone) or a pharmaceutically acceptable salt thereof, and/or an enantiomer thereof, and/or an isotopologue thereof, and/or an isotopomer thereof, and/or a solvate thereof, and/or a polymorph thereof and/or a prodrug thereof in a therapeutically effective amount that results in a plasma AUC0-24 of methylone of 47-10,983 ng·h/mL in the subject.
-150. (canceled)
Dependencies are inferred from the claim text.